Search

Your search keyword '"Kiyohito Takahashi"' showing total 5 results
Start Over Author "Kiyohito Takahashi" Topic internal medicine
5 results on '"Kiyohito Takahashi"'

1. Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes

Author

Hirokatsu Niwa, Shin Aoki, Arina Miyoshi, Aika Miya, Kiyohiko Takahashi, Akinobu Nakamura, Hideaki Miyoshi, Kyu Yong Cho, Yoichi M. Ito, Naoki Manda, Hiroshi Nomoto, Tatsuya Atsumi, Chiho Yamamoto, Yoshio Kurihara, and Kiyohito Takahashi

Subjects
Blood Glucose, Male, Epidemiology, Endocrinology, Diabetes and Metabolism, Type 2 diabetes, 030204 cardiovascular system & hematology, Sodium-glucose cotransporter 2 inhibitor, Body Mass Index, chemistry.chemical_compound, Glycated hemoglobin, 0302 clinical medicine, Glucosides, Japan, Sulfonylurea, Prospective Studies, Articles, General Medicine, Middle Aged, Prognosis, Original Article, Drug Therapy, Combination, Female, medicine.medical_specialty, medicine.drug_class, 030209 endocrinology & metabolism, Thiophenes, Diseases of the endocrine glands. Clinical endocrinology, 03 medical and health sciences, Internal medicine, Diabetes mellitus, Internal Medicine, medicine, Humans, Sodium-Glucose Transporter 2 Inhibitors, Glycemic, business.industry, Body Weight, RC648-665, medicine.disease, Discontinuation, Sodium–glucose cotransporter 2 inhibitor, Sulfonylurea Compounds, Ipragliflozin, Diabetes Mellitus, Type 2, chemistry, Propensity score matching, business, Biomarkers, Follow-Up Studies
Abstract

Aims/Introduction We investigated the difference in efficacy and safety between discontinuation and maintaining of sulfonylurea when adding a sodium–glucose cotransporter 2 inhibitor. Materials and Methods In the present multicenter, prospective observational study, 200 patients with type 2 diabetes treated with sulfonylurea and with a need to add ipragliflozin were enrolled and divided into two groups: discontinued sulfonylurea (Discontinuation group) or maintained sulfonylurea, but at the lowest dose (Low‐dose group) when adding ipragliflozin. We compared the two groups after 24 weeks using propensity score matching to adjust for differences between the groups. Results In the matched cohort (58 patients in each group), baseline characteristics of both groups were balanced. The primary outcome of the proportion of patients with non‐exacerbation in glycated hemoglobin after 24 weeks was 91.4% in the Low‐dose group and 75.9% in the Discontinuation group, a significant difference (P = 0.024). However, bodyweight was significantly decreased in the Discontinuation group compared with the Low‐dose group (−4.4 ± 2.1 kg vs −2.9 ± 1.9 kg, P

Published
2018
Full Text
View/download PDF

2. Effects of linagliptin monotherapy compared with voglibose on postprandial blood glucose responses in Japanese patients with type 2 diabetes: Linagliptin Study of Effects on Postprandial blood glucose (L-STEP)

Author

Yoshio Fujitani, Takahisa Hirose, Hiroaki Satoh, Masumi Ai, Hirotaka Watada, Kiyohito Takahashi, Tomoya Mita, Yosuke Okada, Toru Hiyoshi, Shimpei Fujimoto, and Masahiko Gosho

Subjects
Adult, Blood Glucose, Male, medicine.medical_specialty, Time Factors, Endocrinology, Diabetes and Metabolism, Linagliptin, 030209 endocrinology & metabolism, Type 2 diabetes, 030204 cardiovascular system & hematology, Fasting glucose, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Double-Blind Method, Japan, Internal medicine, Diabetes mellitus, Voglibose, Internal Medicine, Humans, Hypoglycemic Agents, Medicine, Retrospective Studies, Glycemic, Dose-Response Relationship, Drug, business.industry, Significant difference, General Medicine, Middle Aged, Postprandial Period, medicine.disease, Postprandial, Diabetes Mellitus, Type 2, Female, business, Inositol, Follow-Up Studies, medicine.drug
Abstract

To compare the efficacy on glycemic parameters between a 12-week administration of once-daily linagliptin and thrice-daily voglibose in Japanese patients with type 2 diabetes.In a multi-center, randomized, parallel-group study, 382 patients with diabetes were randomized to the linagliptin group (n=192) or the voglibose group (n=190). A meal tolerance test was performed at weeks 0 and 12. Primary outcomes were the change from baseline to week 12 in serum glucose levels at 2h during the meal tolerance test, HbA1c levels, and serum fasting glucose levels, which were compared between the 2 groups.Whereas changes in serum glucose levels at 2h during the meal tolerance test did not differ between the groups, the mean change in HbA1c levels from baseline to week 12 in the linagliptin group (-0.5±0.5% [-5.1±5.4mmol/mol]) was significantly larger than in the voglibose group (-0.2±0.5% [-2.7±5.4mmol/mol]). In addition, there was significant difference in changes in serum fasting glucose levels (-0.51±0.95mmol/L in the linagliptin group vs. -0.18±0.92mmol/L in the voglibose group, P0.001). The incidences of hypoglycemia, serious adverse events (AEs), and discontinuations due to AEs were low and similar in both groups. However, gastrointestinal AEs were significantly lower in the linagliptin group (1.05% vs. 5.85%; P=0.01).These data suggested that linagliptin monotherapy had a stronger glucose-lowering effect than voglibose monotherapy with respect to HbA1c and serum fasting glucose levels, but not serum glucose levels 2h after the start of the meal tolerance test.

Published
2016
Full Text
View/download PDF

3. Effects of linagliptin versus voglibose on treatment-related quality of life in patients with type 2 diabetes: sub-analysis of the L-STEP study

Author

Toru Hiyoshi, Hirotaka Watada, Hitoshi Ishii, Shimpei Fujimoto, Hideki Nishimura, Masahiko Gosho, Tomoya Mita, Yoshio Fujitani, Toshiki Matsubara, Masumi Ai, Takahisa Hirose, Kiyohito Takahashi, Hisamoto Kuroda, Hiromasa Goto, Hiroaki Satoh, and Yosuke Okada

Subjects
Blood Glucose, Male, medicine.medical_specialty, medicine.drug_class, Endocrinology, Diabetes and Metabolism, 030209 endocrinology & metabolism, Linagliptin, Type 2 diabetes, Dipeptidyl peptidase-4 inhibitor, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Quality of life, Diabetes management, Internal medicine, Diabetes mellitus, Voglibose, Activities of Daily Living, Medicine, Humans, Hypoglycemic Agents, Aged, Alpha-glucosidase inhibitor, Glycated Hemoglobin, Dipeptidyl-Peptidase IV Inhibitors, business.industry, Middle Aged, medicine.disease, Treatment Outcome, Diabetes Mellitus, Type 2, Quality of Life, Female, business, Inositol, medicine.drug
Abstract

Treatment-related quality of life (QOL) is an important aspect of diabetes management. However, no studies have compared the influence of dipeptidyl peptidase-4 inhibitors versus alpha-glucosidase inhibitors on treatment-related QOL. This prespecified sub-analysis of the Linagliptin Study of Effects on Postprandial blood glucose (L-STEP) compared the effects of linagliptin (5 mg once daily) and voglibose (0.2 mg/meal thrice daily) on treatment-related QOL in Japanese patients with type 2 diabetes (T2DM) inadequately controlled with diet and exercise therapy. Among 366 subjects in the original study, 182 in the linagliptin group and 173 in the voglibose group were included in this analysis. The outcome of this study was change in QOL as assessed by the Diabetes Therapy-Related Quality of Life 17 (DTR-QOL17) questionnaire from baseline to week 12. Compared with baseline data, total DTR-QOL17 scores were significantly higher after 12 weeks of linagliptin and voglibose treatment. The change in the total DTR-QOL17 score and the score of one domain, burden on social activities and daily activities, was significantly greater in the linagliptin group than in the voglibose group. In addition, only linagliptin treatment was identified as a factor associated with an increased total DTR-QOL17 score. Linagliptin is superior to voglibose in terms of improving treatment-related QOL in Japanese patients with T2DM.

Published
2018

4. Comparative Clinical Study of Cefpiramide (SM-1652) and Cefmetazole for Respiratory Tract Infections by a Double-Blind Method

Author

Hiroyuki KOBAYASHI, Osamu KITAMOTO, Akira SAITO, Yasumichi KATO, Masumi TOMIZAWA, Ichiro NAKAYAMA, Morikuni ABE, Akira UJIIE, Yoshio KINOSHITA, Osamu YAJIMA, Fumio NAGAHAMA, Yuichi SASAKI, Shinya YASUDA, Takehito NAKABAYASHI, Takahisa SAITO, Satoshi YAGUCHI, Kazuo SAOTOME, Yuji IKEDA, Jutaro SHIMOMURA, Mitsuharu OGI, Hiroshi TAKAGI, Akihiko KUZE, Osamu MITSUHASHI, Takashi TAKABORI, Yomei HIRAGA, Kohki KIKUCHI, Hiroshi KAWAI, Kazuo TAKEBE, Kenichi IMAMURA, Yoshihiro KUMASAKA, Kiyohito TAKAHASHI, Hisashi NAKAHATA, Mitsuo NAKAMURA, Takashi CHINOI, Katsuhiro OKAMOTO, Shuichiro YOSHIDA, Naoyoshi MASAKI, Toyokazu TAMURA, Tadashi MIYAZAWA, Hazime WATANABE, Shiro KOSAKA, Makoto NAKAZONO, Tsuneharu BABA, Kazuo SASAKI, Morio SAGARA, Hitoshi YASHIRO, Osamu UEHARA, Masao TAMURA, Ryuji ITO, Taro CHIBA, Kazuki KONISHI, Toshimi SUZUKI, Yoshiaki TAKEZAWA, Yasuo ONO, Hisao KIMURA, Tamotsu TAKISHIMA, Kiyoshi KONNO, Kotaro OIZUMI, Akira WATANABE, Seiichi AONUMA, Kikuo ONUMA, Izumi HAYASHI, Tatsuya ABE, Masataka KATSU, Kenichi OKAYAMA, Kunio IMATAKA, Masanori ADACHI, Fuyuhiko HIGASHI, Hideo IKEMOTO, Kazuyoshi WATANABE, Junko HIBINO, Yasushi UEDA, Atsushi SAITO, Masanobu KAJI, Tadashi MIYAHARA, Ryozo YONEDA, Mitsuo KAWAMURA, Sumio YAMAOKA, Keimei MASHIMO, Keiichi NAKAGAWA, Masaru KOYAMA, Kentaro WATANABE, Motoichi TANAKA, Shinichi ODAMA, Junzaburo KABE, Hiroyoshi ISHIBASHI, Hiroichi TANIMOTO, Akio TACHIBANA, Ippei FUJIMORI, Michinori KOHNO, Yoshio KOBAYASHI, Toshio FUKUI, Kenji MITSUI, Kokichi FUKUSHIMA, Akira ITHO, Kunihiko SHINDO, Shigeki ODAGIRI, Makio KURIHARA, Hideyuki HASEGAWA, Kazufuto FUKAYA, Hajimu TAKEDA, Osamu SEKINE, Yoshimaru USUDA, Nobuki AOKI, Fusanosuke YAMASAKU, Yasutoshi SUZUKI, Kaoru OHYAMA, Kuniyoshi SUZUKI, Ryusaku SHIMIZU, Toshiyuki YAMAMOTO, Saburo KITAURA, Masahito KATO, Kenzo SUZUKI, Kazuo YOSHITOMO, Motoko YAMAMOTO, Akihiko KISHIMOTO, Nobuo MAEKAWA, Michiyasu NAKANISHI, Takekuni IWATA, Mitsuo HASE, Ryoichi AMIYA, Yoichi OSADA, Hiroshi OKUBO, Yuruko OKAMOTO, Yoshihiro UEDA, Keigo MAEHARA, Fumio MIKI, Rinzo SOEJIMA, Yoshito NIKI, Masayasu KAWANISHI, Chikara NAKAHAMA, Yukio NISHIMOTO, Michio YAMAKIDO, Fumiaki TSUKIYAMA, Osamu KURIMURA, Hideo SASAKI, Yoshihiko ARAYA, Yoko KAGAWA, Eiro TSUBURA, Toshihiro GOTO, Yoshihiro TAKISHITA, Yoshiro SAWAE, Kaoru OKADA, Nobuaki SHIGEMATSU, Osamu OGUSHI, Kohei HARA, Tsuneo TSUTSUMI, Kazuhiro OKUNO, Rokushi OKA, Keizo YAMAGUCHI, Youji SUZUYAMA, Toshiyuki OE, Yoshiteru SHIGENO, Naomi ITOH, Hikaru TANAKA, Masao SAI, Keizo MATSUMOTO, Harumi SHISHIDO, Tsuneo ISHIBASHI, Masahiro TAKAMOTO, Atsushi SHINODA, Hitoshi NAGANO, Toshiyuki HAYASHI, Haruhiko TOKUOMI, Yasutsugu FUKUDA, and Katsumasa TOKUNAGA

Subjects
Double blind, Clinical study, medicine.medical_specialty, Respiratory tract infections, business.industry, Internal medicine, medicine, General Medicine, Cefpiramide, Cefmetazole, business, Gastroenterology, medicine.drug
Published
1983
Full Text
View/download PDF

5. [A well-controlled comparative study on ceftriaxone with cefotaxime in respiratory tract infections]

Author

Hiroyuki KOBAYASHI, Kenji TAKAMURA, Hiroshi OSHITANI, Tomoko NIHEI, Akira SAITO, Masumi TOMIZAWA, Ichiro NAKAYAMA, Kiyofumi ISHIKAWA, Morikuni ABE, Yoshihiko KURODA, Hiroyuki KUMANO, Yoshio KURIHARA, Tuyoshi KIKUIRI, Shuzaburo FUKUYAMA, Fumio NAGAHAMA, Shinya YASUDA, Akira SUZUKI, Yomei HIRAGA, Mitsuharu OGI, Akihiko KUZE, Hiroshi KON, Katsuo SUZUKI, Rensuke KURODA, Jutaro SHIMOMURA, Kazuo TAKEBE, Seiichi MURAKAMI, Morio SAGARA, Masahiro TSUTSUI, Shunichi MAEDA, Seiichi OHHIRA, Mitsuo MASUDA, Yuzo MORI, Kazuo SASAKI, Mitsuo SUZUKI, Makoto NAKAZONO, Kiyohito TAKAHASHI, Hisashi NAKAHATA, Shirou KOSAKA, Masao TAMURA, Takashi ITO, Takehisa MURAKAMI, Kohtaro ITAKURA, Tamotsu TAKISHIMA, Shiroh IDA, Kiyoshi KONNO, Kikuo ONUMA, Kotaro OIZUMI, Masako SASAKI, Akira WATANABE, Seiichi AONUMA, Reiko SASAKI, Izumi HAYASHI, Masataka KATSU, Keimei MASHIMO, Yoshiji YAMANE, Sumio YAMAOKA, Atsushi SAITO, Jingoro SHIMADA, Koya SHIBA, Takehisa YAMAJI, Toshio HOJO, Masanobu KAJI, Tadashi MIYAHARA, Hideo IKEMOTO, Kazuyoshi WATANABE, Keiichi NAKAGAWA, Kentaro WATANABE, Masaru KOYAMA, Fukuo IJIMA, Kaoru SHIMADA, Takashi INAMATSU, Kyoko URAYAMA, Hiroichi TANIMOTO, Kunihiko YOSHIMURA, Tatsuo NAKATANI, Naohiko CHONABAYASHI, Yoshitaka NAKAMORI, Koichiro NAKATA, Junzaburo KABE, Hiroyoshi ISHIBASHI, Yasuyuki SANO, Ippei FUJIMORI, Yoshio KOBAYASHI, Akio ONAKA, Kazufuto FUKAYA, Shigeki ODAGIRI, Kouu MUROHASHI, Hirotada IKEDA, Kaneo SUZUKI, Tamotsu KANEKO, Toshihiko TAKEUCHI, Toshiyuki YAMAMOTO, Masahito KATO, Kouichi WADA, Masaaki ARAKAWA, Osamu SEKINE, Yoshimaru USUDA, Nobuki AOKI, Fusanosuke YAMASAKU, Yasutoshi SUZUKI, Kaoru OYAMA, Nobuo MAEKAWA, Michiyasu NAKANISHI, Yujiro SUZUKI, Keijyu LEE, Hiroshi OKUBO, Yoshihiro UEDA, Yuruko OKAMOTO, Keigo MAEHARA, Seibun YONEZU, Yube IIDA, Fumio MIKI, Yoshiyasu IKUNO, Eiji INOUE, Minoru YOSHIYAMA, Tetsuto MURATA, Shinichi TANIZAWA, Kazuo SAKAMOTO, Rinzo SOEJIMA, Yoshito NIKI, Osamu KURIMURA, Hideo SASAKI, Hirofumi FUKUHARA, Eiro TSUBURA, Masakazu TAMURA, Masaru NAKAGAWA, Yoshiro SAWAE, Kaoru OKADA, Yukio KUMAGAI, Hitoshi NAGANO, Chiharu KUBO, Takashi ITOGA, Masaru NASU, Jun GOTO, Yoichiro GOTO, Takayoshi TASHIRO, Kohei HARA, Keizo YAMAGUCHI, Yoji SUZUYAMA, Yoshiteru SHIGENO, Toshiyuki OYE, Hiromaru IWASAKI, Toshiaki HAYASHI, Keizo MATSUMOTO, Yukio NOGUCHI, and Mikio TAGUCHI

Subjects
Adult, Male, medicine.medical_specialty, Cefotaxime, Respiratory tract infections, business.industry, Ceftriaxone, General Medicine, Middle Aged, Internal medicine, Medicine, Drug Evaluation, Humans, Female, business, Respiratory Tract Infections, medicine.drug, Aged
Published
1986

Catalog

Books, media, physical & digital resources
See catalog results